Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
I-Mab Adr (IMAB)
:IMAB
Holding IMAB?
Track your performance easily
IMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.84 - $2.31
Previous CloseN/A
Volume876.01K
Average Volume (3M)547.16K
Market Cap
$84.73M
Enterprise ValueN/A
Total Cash (Recent Filing)$574.17M
Total Debt (Recent Filing)$114.01M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Mar 26, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.55
Shares Outstanding80,882,910
10 Day Avg. Volume740,938
30 Day Avg. Volume547,165
Standard Deviation0.20
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.00Price Target Upside417.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
I-MAB News
PremiumCompany Announcements
I-Mab Board Chairman to Acquire $2 Million in ADSs
PremiumCompany Announcements
I-Mab Prioritizes Givastomig as Lead Program in Strategic Shift
PremiumCompany Announcements
I-Mab Biopharma’s Strategic Shift to US-Based Biotech
PremiumCompany Announcements
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies
PremiumCompany Announcements
I-Mab’s Promising Q3 Results and Strategic Moves
Ownership Overview
5.60%
Insiders
0.03% Mutual Funds
14.15% Other Institutional Investors
80.22% Public Companies and Individual Investors
IMAB FAQ
What was I-Mab Adr’s price range in the past 12 months?
I-Mab Adr lowest stock price was $0.84 and its highest was $2.31 in the past 12 months.
What is I-Mab Adr’s market cap?
I-Mab Adr’s market cap is $84.73M.
When is I-Mab Adr’s upcoming earnings report date?
I-Mab Adr’s upcoming earnings report date is Mar 26, 2025 which is in 76 days.
How were I-Mab Adr’s earnings last quarter?
Currently, no data Available
Is I-Mab Adr overvalued?
According to Wall Street analysts I-Mab Adr’s price is currently Undervalued.
Does I-Mab Adr pay dividends?
I-Mab Adr does not currently pay dividends.
What is I-Mab Adr’s EPS estimate?
I-Mab Adr’s EPS estimate is -0.06.
How many shares outstanding does I-Mab Adr have?
I-Mab Adr has 80,882,910 shares outstanding.
What happened to I-Mab Adr’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of I-Mab Adr?
Currently, no hedge funds are holding shares in IMAB
---
I-MAB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (417.24% Upside)
$6.00 (417.24% Upside)
Blogger Sentiment
Bullish
IMAB Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.58%
12-Months-Change
Fundamentals
Return on Equity
-39.60%
Trailing 12-Months
Asset Growth
-47.49%
Trailing 12-Months
Company Description
I-Mab Adr
I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.
---
IMAB Stock 12 Month Forecast
Average Price Target
$6.00
▲(417.24% Upside)
Technical Analysis
Best Analysts Covering IMAB
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-57.77%
reiterated a buy rating 4 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.77% per trade.
---